Get notified of page updates

Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Clinicaltrials.gov identifier:
NCT05252390
PRINTER FRIENDLY PAGE

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Clinicaltrials.gov identifier:
NCT05252390
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

NOTE: This study is no longer recruiting patients. 

 

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a in people with advanced . The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or cancers only. 

 

 

 

This Study is Open To:

NOTE: This study is no longer recruiting patients. 

This Study is NOT Open To:

NOTE: This study is no longer recruiting patients.